B. Riley analyst Jeff Van Sinderen downgraded Biote (BTMD) to Neutral from Buy with a price target of $4, down from $8. The company reported a mixed Q2 and lowered its fiscal 2025 outlook, the analyst tells investors in a research note. The firm says a high attrition rate of established clinics, lower procedure volume, and a low rate of new clinic acquisition hindered Biote’s Q2. Riley is unsure of the time it will take the company to achieve sustainable growth of quality new practitioner adds and procedures.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTMD: